Abstract
Grunberg and associates (1) in 1961, first described the polypeptide antifungal agent, X5079C (also referred to as R02-7758), produced by a species of Streptomyces, and active in experimental infections with Histoplasma capsulatum and Blastomyces dermatitidis in mice. Emmons (2) confirmed these observations and in addition found the drug active in infection with Coccidioides immitis and Sporotrichum schenckii in mice. These studies were followed by the demonstration of the drug's chemotherapeutic activity (3) and side effects ( 4) in 27' patients with systemic mycoses. The present report is a follow-up on these 27 and presents data on an additional12 patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
